Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension

Journal of Human Hypertension

Volumn 19, Issue 2, 2005, Pages 149-154

  Bautista, L E ^a,b   Vera, L M ^c   Arenas, I A ^d   Gamarra, G ^c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Blood pressure; C reactive protein; Interleukin 6; Risk factors; TNF

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BODY MASS; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FAMILY HISTORY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION RISK; PROSPECTIVE STUDY; RANDOMIZATION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLOMBIA; FEMALE; HUMANS; HYPERTENSION; INTERLEUKIN-6; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13544259939     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001785     Document Type: Article

References (39)

1. Ridker PM et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
2. Ridker PM et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
3. Ridker PM et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
4. Harris TB et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512.
5. Volpato S et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 2001; 103: 947-953.
6. Bautista LE et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-861.
7. Chul SK et al. High sensitivity c-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429-433.
8. Bautista LE et al. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis 2004; 15 (in press).
9. Rifai N et al. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 1999; 45: 1967-1973.
10. Chae CU et al. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.
11. Ito H et al. Association of serum tumour necrosis factor-alpha with serum low-density lipoprotein-cholesterol and blood pressure in apparently healthy Japanese women. Clin Exp Pharmacol Physiol 2001; 28: 188-192.
12. Furumoto T et al. Association of cardiovascular risk factors and endothelial dysfunction in japanese hypertensive patients: implications for early atherosclerosis. Hypertens Res 2002; 25 475-480.
13. Mendall MA et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 273-277.
14. Sheu WHH et al. Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects. Clin Exp Hypertens 2000; 22: 595-606.
15. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
16. Bautista L et al. Prevalencia de Factores de Riesgo para Enfermedades Crónicas No Transmisibles en la Población de Bucaramanga. Encuesta Basal del Programa CARMEN. UIS 2000. Bucaramanga.
17. Perloff D et al. Human blood pressure determination by sphygmomanometry. Circulation 1993; 88: 2460-2470.
18. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol 1986; 123: 174-184.
19. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340-349.
20. Tsiatis AA. A note on a goodness-of-fit test for the logistic regression model. Biometrika 1980; 67: 250-251.
21. Yudkin JS et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
22. Fernandez-Real JM et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001; 86: 1154-1159.
23. Woods A et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574-1583.
24. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18: 428-432.
25. Fishman D et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
26. Brull DJ et al. The effect of the interleukin-6-174G>C promoter gene polymorphism on endothelial function in healthy volunteers. Eur J Clin Invest 2002; 32: 153-157.
27. Humphries SE et al. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22: 2243-2252.
28. Losito A et al. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003; 64: 616-622.
29. Pola R et al. The -174 G/C polymorphism of the interleukin-6 gene promoter and essential hypertension in an elderly Italian population. J Hum Hypertens 2002; 16: 637-640.
30. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.
31. Hingorani AD et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-999.
32. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: Epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223-230.
33. Fernandez-Real JM et al. Shedding of TNF-alpha receptors, blood pressure, and insulin sensitivity in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2002; 282: 952-959.
34. Yoshizumi M et al. Tumor necrosis factor down-regulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
35. Dalziel B et al. Association of the TNF-alpha -308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 2002; 10: 401-407.
36. Ford ES. C-reactive protein concentration and cardiovascular disease risk factors in children: findings from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2003; 108 1053-1058.
37. Nomura S et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
38. Sterpetti AV et al. Shear stress increases the release of interleukin-1 and interleukin-6 by aortic endothelial cells. Surgery 1993; 114: 911-914.
39. Engstrom G et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002; 22: 2054-2058.